Table 1.
Characteristics of patients with psoriatic arthritis. Unless otherwise stated, values are presented as median (min-max)*
| Parameter | Patients (n = 160) |
|---|---|
| Age, years (mean ± standard deviation) |
46.49 ± 11.12 |
| Female, n (%) |
121 (75.6) |
| Disease duration, years |
2 (0.5-34) |
| Presence of psoriasis, n (%) |
122 (76.3) |
| Psoriatic Arthritis Impact of Disease 0-10 |
5.55 (1.05-9.65) |
| Treatment, n (%) |
|
| NSAIDs |
15 (9.4) |
| NSAIDs + csDMARDs |
114 (71.3) |
| bDMARDs |
17 (10.6) |
| csDMARDs + bDMARDs |
14 (8.8) |
| Disease Activity Index for Psoriatic Arthritis |
21.91 (10-129) |
| CRP, mg/L |
4.67 (0.12-82.77) |
| Erythrocyte sedimentation rate, mm/h |
10 (2-52) |
| CAR |
1.01 (0.03-19.61) |
| Neutrophil/lymphocyte ratio |
2.41 (0.73-7.10) |
| Platelet/lymphocyte ratio |
134.55 (47.47-492.16) |
| Hemoglobin, g/dL (mean ± SD) |
13.61 ± 1.72 |
| Sacroiliitis, n (%) |
|
| bilateral |
52 (32.5) |
| right |
36 (22.5) |
| left |
24 (15) |
| absence | 48 (30) |
*Abbreviations: bDMARDs – biological disease-modifying antirheumatic drugs; CAR – CRP/albumin ratio; CRP – C-reactive protein; csDMARDs – conventional disease-modifying antirheumatic drugs; NSAIDs – non-steroidal anti-inflammatory drugs.